January 7, 2025

Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma – National Cancer Institute (.gov)

January 4, 2025

Meet Jeff Levinson, the Spirit of Hope Honoree for the MMRF Walk/Run: Detroit

Jeff is a husband, father, and grandfather who lives with multiple myeloma every day. Despite his challenges, he faces them with optimism and a smile. Having gone through a long journey with the illness, Jeff shares his experiences, both the highs and lows, with a positive and enthusiastic attitude. His goal is to help others […]

January 3, 2025

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial – Nature

December 27, 2024

Statement from The Multiple Myeloma Research Foundation (MMRF) on Distinguished Business Leader Richard Parsons

We are deeply saddened about the passing of Richard “Dick” Parsons, a prominent and accomplished leader who held top posts at Time Warner and Citigroup among other companies. Dick was a very close friend to and long-time supporter of the Multiple Myeloma Research Foundation. Diagnosed with multiple myeloma in 2015, Dick soon became a strong […]

December 23, 2024

Sarclisa (isatuximab): A New Option for Patients With Newly Diagnosed Myeloma Not Eligible for Transplant

In September 2024, Sarclisa (isatuximab) became the first drug to be approved by the FDA for use with Velcade, Revlimid, and dexamethasone (Isa-VRd) for adult patients who are newly diagnosed with multiple myeloma but unable to receive high-dose chemotherapy and a stem cell transplant commonly used in myeloma treatment. With this new approval, patients with […]